RZLT

What one share of Rezolute holds

Pharmaceutical Preparations

Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”).

Rezolute’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Profit−$0.75
Cash and investments$1.12
Book value$1.04

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2013—−$54.21———−$31.22
2014—−$51.84———$17.71
2015—−$27.12———$18.60
2016—−$42.20———$12.49
2017—−$28.68———$8.66
2018—−$26.83$0.01−$12.68——
2020—−$3.54$0.00−$4.20—$1.26
2021—−$2.72———$3.12
2022—−$2.32———$4.45
2023—−$1.01$0.00−$0.87—$3.15
2024—−$1.33———$2.27
2025—−$0.98———$1.86
2026—−$0.75———$1.04

Common questions about Rezolute

How much does one share of Rezolute earn?

Over its latest fiscal year, Rezolute lost $0.75 for each share.

Does Rezolute pay a dividend?

Rezolute didn’t pay a dividend over its latest fiscal year, according to its SEC filings.

What is Rezolute’s book value per share?

Rezolute’s book value is $1.04 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of Rezolute have?

Each share of Rezolute has $1.12 of cash and investments, as of June 30, 2026.

Has Rezolute bought back shares?

Rezolute’s share count rose about 83634% from 2013 to 2026. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.